Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

被引：4

作者：

Ge, Jennifer Y. ^{[1
,2
,3
]}

Overmoyer, Beth ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Susan F Smith Ctr Womens Cancers, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Harvard Med Sch, Harvard MIT Div Hlth Sci & Technol, Boston, MA 02115 USA

来源：

CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 02期

关键词：

Inflammatory breast cancer; HER2-positive breast cancer; Anti-HER2; therapy; Metastatic disease; Stage IV; TRASTUZUMAB EMTANSINE; PLUS;

D O I：

10.1159/000516760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven by the advent of novel targeted therapies. Here, we present two patients who have survived for over 10 years after being diagnosed with de novo metastatic HER2-positive IBC. We review the data for the treatments available for metastatic HER2-positive IBC and the evolving treatment recommendations for this disease.

引用

页码：1071 / 1079

页数：9

共 50 条

[31] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
Church, David N.
Price, Chris G. A.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
[32] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
Tina Nie
Hannah A. Blair
Targeted Oncology, 2023, 18 : 463 - 470
[33] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
Nie, Tina
Blair, Hannah A.
TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
[34] Systemic treatment of HER2-positive metastatic breast cancer: A systematic review
Wilcken, Nicholas
Zdenkowski, Nicholas
White, Michelle
Snyder, Ray
Pittman, Ken
Mainwaring, Paul
Green, Michael
Francis, Prudence
De Boer, Richard
Colosimo, Maree
Chua, Sue
Chirgwin, Jacquie
Beith, Jane
Bell, Richard
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 14
[35] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
P. S. Blanchette
D. N. Desautels
G. R. Pond
J. M. S. Bartlett
S. Nofech-Mozes
M. J. Yaffe
K. I. Pritchard
Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
[36] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
Blanchette, P. S.
Desautels, D. N.
Pond, G. R.
Bartlett, J. M. S.
Nofech-Mozes, S.
Yaffe, M. J.
Pritchard, K. I.
BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 169 - 177
[37] Characteristics and survival of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Elvira Montoya-Restrepo, Maria
Gomez Wolff, Luis Rodolfo
Sanchez Jimenez, Astrid Viviana
Garcia Garcia, Hector Ivan
REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (03): : 112 - 118
[38] Addition of Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients With Metastatic, HER2-Positive Breast Cancer
Printz, Carrie
CANCER, 2020, 126 (10) : 2113 - 2113
[39] Pure mucinous breast cancer HER2-positive, a case report
Gonzalez Aranda, A. M.
Martinez Gomez, E.
Santana Costa, A.
Arnanz Velasco, F.
Gonzalez de Diego, M. H.
Zapico Goni, A.
CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA, 2021, 48 (04):
[40] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
Blanchette, P. S.
Desautels, D. N.
Pond, G.
Bartlett, J. M. S.
Nofech-Mozes, S.
Yaffe, M.
Pritchard, K. I.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →